María Inmaculada Zas-García, José Manuel Fernández-Carreira, Jorge Rodríguez-Prida, Ana Blanco-Suárez, Marcos Álvarez-Pérez, Jesús Rubio-Sanz, Elsa Castelo-Alvárez, Daniel González-Fernández, Tania Rubio-Alfonso
Objective: To evaluate how antimicrobial consumption was influenced by increasing the frequency of meetings in which the Antimicrobial Stewardship Program (ASP) team conducted prospective audit and feedback (PAF).
Materials and methods: Retrospective cohort study comparing consumption in DDD per 1000 beds-day and DDD per 1000 admissions across groups of anti-infectives, antibacterial groups, agents against methicillin-susceptible Staphylococcus aureus (anti-MSSA agents)/agents against methicillin-resistant Staphylococcus aureus (anti-MRSA agents), antibiotics targeting sensitive Gram-negative bacteria/antibiotics targeting resistant Gram-negative bacteria and antimicrobial agents, during two comparative periods of ASP activity (2 weekly meetings in 2023 versus 1 weekly meeting in 2022).
Results: Comparing 2023 to 2022: antibacterials for systemic use consumption increased in DDD per 1000 beds-day (+0.13%) and decreased in DDD per 1000 admissions (-3.55 %); consumption in DDD per 1000 beds-day and DDD per 1000 admissions increased for penicillins, glycopeptides and aminoglycosides while it decreased for cephalosporins and carbapenems, quinolones use increased per beds-days but decreased per admissions; regarding anti-MSSA and anti-MRSA agents, consumption of cefazolin, cloxacillin, vancomycin and daptomycin increased in DDD per 1000 beds-day and DDD per 1000 admissions, linezolid consumption increased per beds-day but decreased per admissions; for antibiotics targeting sensitive Gram-negative bacteria and antibiotics targeting resistant Gram-negative bacteria, consumption of amoxicillin-clavulanate, piperacillin-tazobactam, aminoglycosides, ceftazidime, cefepime and polymyxins increased per DDD/1000 bed-days and DDD per 1000 admissions, carbapenems consumption decreased per bed-days and admissions.
Conclusions: The increase in the frequency of meetings seems to be related to better use of antimicrobials in our center.
{"title":"[Impact of increasing the frequency of meetings in which the Antimicrobial Stewardship Programme team conducted prospective audit and feedback on antimicrobial consumption].","authors":"María Inmaculada Zas-García, José Manuel Fernández-Carreira, Jorge Rodríguez-Prida, Ana Blanco-Suárez, Marcos Álvarez-Pérez, Jesús Rubio-Sanz, Elsa Castelo-Alvárez, Daniel González-Fernández, Tania Rubio-Alfonso","doi":"10.37201/req/022.2025","DOIUrl":"10.37201/req/022.2025","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate how antimicrobial consumption was influenced by increasing the frequency of meetings in which the Antimicrobial Stewardship Program (ASP) team conducted prospective audit and feedback (PAF).</p><p><strong>Materials and methods: </strong>Retrospective cohort study comparing consumption in DDD per 1000 beds-day and DDD per 1000 admissions across groups of anti-infectives, antibacterial groups, agents against methicillin-susceptible <i>Staphylococcus aureus</i> (anti-MSSA agents)/agents against methicillin-resistant <i>Staphylococcus aureus</i> (anti-MRSA agents), antibiotics targeting sensitive Gram-negative bacteria/antibiotics targeting resistant Gram-negative bacteria and antimicrobial agents, during two comparative periods of ASP activity (2 weekly meetings in 2023 versus 1 weekly meeting in 2022).</p><p><strong>Results: </strong>Comparing 2023 to 2022: antibacterials for systemic use consumption increased in DDD per 1000 beds-day (+0.13%) and decreased in DDD per 1000 admissions (-3.55 %); consumption in DDD per 1000 beds-day and DDD per 1000 admissions increased for penicillins, glycopeptides and aminoglycosides while it decreased for cephalosporins and carbapenems, quinolones use increased per beds-days but decreased per admissions; regarding anti-MSSA and anti-MRSA agents, consumption of cefazolin, cloxacillin, vancomycin and daptomycin increased in DDD per 1000 beds-day and DDD per 1000 admissions, linezolid consumption increased per beds-day but decreased per admissions; for antibiotics targeting sensitive Gram-negative bacteria and antibiotics targeting resistant Gram-negative bacteria, consumption of amoxicillin-clavulanate, piperacillin-tazobactam, aminoglycosides, ceftazidime, cefepime and polymyxins increased per DDD/1000 bed-days and DDD per 1000 admissions, carbapenems consumption decreased per bed-days and admissions.</p><p><strong>Conclusions: </strong>The increase in the frequency of meetings seems to be related to better use of antimicrobials in our center.</p>","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"305-318"},"PeriodicalIF":0.0,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12257185/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144164331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
José Carlos De Gracia-Díaz, Ana Madueño, Sara Díaz-Martín, María Lecuona-Fernández
{"title":"[Early diagnosis of a case of septic arthritis thanks to the BioFire® joint infection panel].","authors":"José Carlos De Gracia-Díaz, Ana Madueño, Sara Díaz-Martín, María Lecuona-Fernández","doi":"10.37201/req/023.2025","DOIUrl":"10.37201/req/023.2025","url":null,"abstract":"","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"355-357"},"PeriodicalIF":0.0,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12257186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144164281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Elena de Rafael-González, Javier Cabañas-Morafraile, Laura Serrano-Martín, Agustín Julián-Jiménez, María Torres-Fernández, Elia Chaves-Prieto, Laura Morell-Jurado, William Esneider López-Forero, María Francisca Calafell-Mas, Álvaro Thomas-Balaguer Cordero, María Remedios Asensio-Nieto, Isabel Nieto-Rojas, Rafael Rubio-Díaz, Eva Heredero-Gálvez, María Carmen Lorenzo-Lozano, Raúl Canabal-Berlanga
Objectives: To analyze and compare the accuracy of midregional proadrenomedullin (MR-proADM) to predict poor clinical outcome (understood as progression to septic shock or admission to the Critical Care Unit -CCU-) and 30-day mortality in adult patients seen for suspected infection in the Emergency Department (ED). We also compared their performance with other biomarkers (C-reactive protein -CRP-, procalcitonin -PCT-, lactate and leukocyte count) and clinical scales widely used in routine practice (qSOFA, SRIS, NEWS-2).
Methods: A prospective, observational and analytical study was carried out on adult patients who were treated in an ED with the clinical diagnosis of an infectious process. Follow-up was carried out for 30 days. The main outcome was a composite measure that included progression to septic shock or admission to the CCU and 30-day mortality. The predictive ability was analyzed with the area under the curve (AUC) of the receiver operating characteristic (ROC) and the values of sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV) of MR-proADM, PCR, PCT, lactate, leukocyte count and the clinical scales.
Results: 214 patients were included, of whom 31 (14.5%) fulfilled the combined variable. The mean age was 68.6 (SD 20.75) years, 55.1% (118) were men. The MR-proADM concentration achieved the best AUC-ROC of 0.920 (95% CI: 0.850-0.989) compared to the other biomarkers and clinical scales. With a cut-off point (Cp) according to the Youden index > 2.105 nmol/L, a Se: 68%, Es: 98% and NPV: 97% were obtained. The NEWS-2 scale ≥ 5 achieves an AUC-ROC of 0.733 (95% CI: 0.630-0.835) with a Se: 87%, Es: 55% and NPV: 96%. The mixed model (MR-proADM ≥2.1 nmol/l + NEWS-2 ≥5) improved the AUC-ROC to 0.849 (95% CI: 0.782-0.915) and Se: 68%, Es: 98%, PPV: 74% and NPV: 88%.
Conclusions: In adult patients attended with clinical suspicion of infection in the ED, MR-proADM presents a high ability to predict poor clinical evolution (progression to septic shock or ICU admission) and 30-day mortality and performs better than PCT, lactate, CRP, leukocyte count and the clinical scales qSOFA, SRIS, NEWS-2. The combined model (MR-proADM ≥2.1 nmol/L + NEWS-2 ≥5) improves prediction of both MR-proADM and clinical scales.
{"title":"[Ability of midregional proadrenomedullin (MR-proADM) to predict poor clinical outcome and stratify prognosis in adult patients seen for suspected infection in the Emergency Department].","authors":"Elena de Rafael-González, Javier Cabañas-Morafraile, Laura Serrano-Martín, Agustín Julián-Jiménez, María Torres-Fernández, Elia Chaves-Prieto, Laura Morell-Jurado, William Esneider López-Forero, María Francisca Calafell-Mas, Álvaro Thomas-Balaguer Cordero, María Remedios Asensio-Nieto, Isabel Nieto-Rojas, Rafael Rubio-Díaz, Eva Heredero-Gálvez, María Carmen Lorenzo-Lozano, Raúl Canabal-Berlanga","doi":"10.37201/req/031.2025","DOIUrl":"10.37201/req/031.2025","url":null,"abstract":"<p><strong>Objectives: </strong>To analyze and compare the accuracy of midregional proadrenomedullin (MR-proADM) to predict poor clinical outcome (understood as progression to septic shock or admission to the Critical Care Unit -CCU-) and 30-day mortality in adult patients seen for suspected infection in the Emergency Department (ED). We also compared their performance with other biomarkers (C-reactive protein -CRP-, procalcitonin -PCT-, lactate and leukocyte count) and clinical scales widely used in routine practice (qSOFA, SRIS, NEWS-2).</p><p><strong>Methods: </strong>A prospective, observational and analytical study was carried out on adult patients who were treated in an ED with the clinical diagnosis of an infectious process. Follow-up was carried out for 30 days. The main outcome was a composite measure that included progression to septic shock or admission to the CCU and 30-day mortality. The predictive ability was analyzed with the area under the curve (AUC) of the receiver operating characteristic (ROC) and the values of sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV) of MR-proADM, PCR, PCT, lactate, leukocyte count and the clinical scales.</p><p><strong>Results: </strong>214 patients were included, of whom 31 (14.5%) fulfilled the combined variable. The mean age was 68.6 (SD 20.75) years, 55.1% (118) were men. The MR-proADM concentration achieved the best AUC-ROC of 0.920 (95% CI: 0.850-0.989) compared to the other biomarkers and clinical scales. With a cut-off point (Cp) according to the Youden index > 2.105 nmol/L, a Se: 68%, Es: 98% and NPV: 97% were obtained. The NEWS-2 scale ≥ 5 achieves an AUC-ROC of 0.733 (95% CI: 0.630-0.835) with a Se: 87%, Es: 55% and NPV: 96%. The mixed model (MR-proADM ≥2.1 nmol/l + NEWS-2 ≥5) improved the AUC-ROC to 0.849 (95% CI: 0.782-0.915) and Se: 68%, Es: 98%, PPV: 74% and NPV: 88%.</p><p><strong>Conclusions: </strong>In adult patients attended with clinical suspicion of infection in the ED, MR-proADM presents a high ability to predict poor clinical evolution (progression to septic shock or ICU admission) and 30-day mortality and performs better than PCT, lactate, CRP, leukocyte count and the clinical scales qSOFA, SRIS, NEWS-2. The combined model (MR-proADM ≥2.1 nmol/L + NEWS-2 ≥5) improves prediction of both MR-proADM and clinical scales.</p>","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"319-334"},"PeriodicalIF":2.2,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12257179/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144164279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Javier Iglesias-Varea, Mario Fernández-Ruiz, Laura Domínguez, Jorge Boán, Eduardo Aparicio-Minguijón, Antonio Terrón, María Asunción Pérez-Jacoiste Asín, José María Aguado, Francisco López-Medrano
Introduction: Infective endocarditis (IE) is a complex condition associated with high morbidity and mortality. The creation of multidisciplinary teams (endocarditis team) has been shown to improve its management and prognosis. We analysed the impact of the formal implementation of a multidisciplinary IE committee (coIE) in a tertiary care hospital.
Methods: Single-centre quasi-experimental study comparing two periods: before (2010-2015) and after (2017-2021) the implementation of the coIE. The coIE met weekly (and on demand when necessary) to make decisions regarding medical and surgical management in patients with definite or possible IE, following a protocol based on international guidelines.
Results: We included 92 and 97 patients in the pre- and post-intervention periods, respectively. Demographic characteristics, predisposing factors, and types of IE were similar. No significant differences were observed in the proportion of patients with surgical indication who underwent surgery (30.2 % vs 39.1 %, respectively; p = 0.317), in-hospital mortality (27.2 % vs 34.0 %; p = 0.308), or one-year mortality (32.6 % vs 45.4 %; p = 0.073). The median (interquartile range) time from diagnosis to surgery decreased in the post-intervention period (11.5 [6.3-25.3] vs 7 [3-10] days; p = 0.026). The diagnosis of embolic events was more frequent in this period (46.7 % vs 58.8 %; p = 0.098).
Conclusions: Although we did not observe a significant impact on mortality among patients with definite IE after the implementation of an endocarditis team, we noted a favourable trend in intermediate indicators of healthcare quality.
感染性心内膜炎(IE)是一种复杂的疾病,具有很高的发病率和死亡率。建立多学科团队(心内膜炎团队)已被证明可以改善其管理和预后。我们分析了在一家三级医院正式实施多学科IE委员会(coIE)的影响。方法:采用单中心准实验研究,比较coIE实施前(2010-2015年)和实施后(2017-2021年)两个时期。coIE每周召开一次会议(必要时根据需要),根据基于国际指南的协议,就明确或可能患有IE的患者的医疗和手术治疗做出决定。结果:我们在干预前和干预后分别纳入了92例和97例患者。人口学特征、诱发因素和IE类型相似。有手术指征的患者接受手术的比例无显著差异(分别为30.2%和39.1%;P = 0.317),住院死亡率(27.2% vs 34.0%;P = 0.308)或一年死亡率(32.6% vs 45.4%;P = 0.073)。干预后,从诊断到手术的中位时间(四分位数范围)缩短了(11.5[6.3-25.3]天和7[3-10]天;P = 0.026)。栓塞事件的诊断在这一时期更为频繁(46.7% vs 58.8%;P = 0.098)。结论:虽然我们没有观察到在心内膜炎团队实施后明确IE患者的死亡率有显著影响,但我们注意到医疗质量的中间指标有良好的趋势。
{"title":"[Impact of a dedicated multidisciplinary committee (<i>endocarditis team</i>) on the management and outcome of infective endocarditis in a reference center].","authors":"Javier Iglesias-Varea, Mario Fernández-Ruiz, Laura Domínguez, Jorge Boán, Eduardo Aparicio-Minguijón, Antonio Terrón, María Asunción Pérez-Jacoiste Asín, José María Aguado, Francisco López-Medrano","doi":"10.37201/req/020.2025","DOIUrl":"10.37201/req/020.2025","url":null,"abstract":"<p><strong>Introduction: </strong>Infective endocarditis (IE) is a complex condition associated with high morbidity and mortality. The creation of multidisciplinary teams (endocarditis team) has been shown to improve its management and prognosis. We analysed the impact of the formal implementation of a multidisciplinary IE committee (coIE) in a tertiary care hospital.</p><p><strong>Methods: </strong>Single-centre quasi-experimental study comparing two periods: before (2010-2015) and after (2017-2021) the implementation of the coIE. The coIE met weekly (and on demand when necessary) to make decisions regarding medical and surgical management in patients with definite or possible IE, following a protocol based on international guidelines.</p><p><strong>Results: </strong>We included 92 and 97 patients in the pre- and post-intervention periods, respectively. Demographic characteristics, predisposing factors, and types of IE were similar. No significant differences were observed in the proportion of patients with surgical indication who underwent surgery (30.2 % vs 39.1 %, respectively; p = 0.317), in-hospital mortality (27.2 % vs 34.0 %; p = 0.308), or one-year mortality (32.6 % vs 45.4 %; p = 0.073). The median (interquartile range) time from diagnosis to surgery decreased in the post-intervention period (11.5 [6.3-25.3] vs 7 [3-10] days; p = 0.026). The diagnosis of embolic events was more frequent in this period (46.7 % vs 58.8 %; p = 0.098).</p><p><strong>Conclusions: </strong>Although we did not observe a significant impact on mortality among patients with definite IE after the implementation of an endocarditis team, we noted a favourable trend in intermediate indicators of healthcare quality.</p>","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"294-304"},"PeriodicalIF":0.0,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12257183/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144164327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-14Epub Date: 2025-02-25DOI: 10.37201/req/121.2024
José Garnacho-Montero, José María Aguado, Enrique Alemparte, Juan P Horcajada, Francisco López-Medrano, Paula Ramírez, Ariadna Giró-Perafita, Martí Blasco, Borja Suberviola
Introduction: Carbapenem-resistant gram-negative bacilli (CRGNB) are one of the main causes of nosocomial infections, posing a major public health challenge. Blood stream infections (BSI) require special attention because of the higher morbidity and mortality associated.
Objective: To assess the impact of initial adequate or inadequate antibiotic treatment on the length of stay (LOS) and healthcare resource utilisation of patients with bloodstream infections (BSI) caused by a Carbapenem-resistant gram-negative bacilli (CRGNB) in the Spanish clinical practice.
Methods: A descriptive, observational, retrospective chart review study of patients diagnosed with CRGNB bacteriemia in 6 Spanish public hospitals.
Results: The overall median LOS of the total population (n=64) was 26.5 days (Q1: 16 days; Q3: 40 days). The median LOS for the initially adequately treated group was 27 days (Q1: 17; Q3: 50), and 24 days (Q1: 15; Q3: 38) for the initially inadequately treated (t-test p= 0.5031). In the Hospital Ward group (n=44), initially adequately treated patients spent hospitalised a median of 6 days less than the initially inadequately treated patients (18 days [Q1: 12; Q3: 27] vs 24 days [Q1: 15; Q3: 38] respectively, p=0.0269). In the total population analysis, initially adequately treated patients had a lower use of resources (20,895.02 [Q1: 11,543.67 ; Q3: 61,773.17 ]) compared to initially inadequately treated patients (24,444.02 [Q1: 11,571.63 ; Q3: 40,790.64 ).
Conclusion: Results suggest that inadequate empirical treatment for BSI caused by CRGNB in the hospital ward could be associated with an increase in the LOS and resource utilization of these patients.
{"title":"Healthcare resource utilization and costs associated with inadequate initial antibiotic treatment of bacteraemia produced by carbapenem-resistant Gram-negative bacilli (CRGNB): a descriptive, observational study in Spanish hospitals.","authors":"José Garnacho-Montero, José María Aguado, Enrique Alemparte, Juan P Horcajada, Francisco López-Medrano, Paula Ramírez, Ariadna Giró-Perafita, Martí Blasco, Borja Suberviola","doi":"10.37201/req/121.2024","DOIUrl":"10.37201/req/121.2024","url":null,"abstract":"<p><strong>Introduction: </strong>Carbapenem-resistant gram-negative bacilli (CRGNB) are one of the main causes of nosocomial infections, posing a major public health challenge. Blood stream infections (BSI) require special attention because of the higher morbidity and mortality associated.</p><p><strong>Objective: </strong>To assess the impact of initial adequate or inadequate antibiotic treatment on the length of stay (LOS) and healthcare resource utilisation of patients with bloodstream infections (BSI) caused by a Carbapenem-resistant gram-negative bacilli (CRGNB) in the Spanish clinical practice.</p><p><strong>Methods: </strong>A descriptive, observational, retrospective chart review study of patients diagnosed with CRGNB bacteriemia in 6 Spanish public hospitals.</p><p><strong>Results: </strong>The overall median LOS of the total population (n=64) was 26.5 days (Q1: 16 days; Q3: 40 days). The median LOS for the initially adequately treated group was 27 days (Q1: 17; Q3: 50), and 24 days (Q1: 15; Q3: 38) for the initially inadequately treated (t-test p= 0.5031). In the Hospital Ward group (n=44), initially adequately treated patients spent hospitalised a median of 6 days less than the initially inadequately treated patients (18 days [Q1: 12; Q3: 27] vs 24 days [Q1: 15; Q3: 38] respectively, p=0.0269). In the total population analysis, initially adequately treated patients had a lower use of resources (20,895.02 [Q1: 11,543.67 ; Q3: 61,773.17 ]) compared to initially inadequately treated patients (24,444.02 [Q1: 11,571.63 ; Q3: 40,790.64 ).</p><p><strong>Conclusion: </strong>Results suggest that inadequate empirical treatment for BSI caused by CRGNB in the hospital ward could be associated with an increase in the LOS and resource utilization of these patients.</p>","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":"38 3","pages":"197-207"},"PeriodicalIF":0.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12095935/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143495133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-14Epub Date: 2025-03-10DOI: 10.37201/req/019.2025
Victoria Lobo-Antuña, Marta Lobo-Antuña, Margarita Monzón-Torres, Sebastián Ortiz-Zuluaga, Armando Mena-Durán, Carmen Ricart-Olmos
{"title":"Cefiderocol-associated chromaturia, a secondary side effect to recognize.","authors":"Victoria Lobo-Antuña, Marta Lobo-Antuña, Margarita Monzón-Torres, Sebastián Ortiz-Zuluaga, Armando Mena-Durán, Carmen Ricart-Olmos","doi":"10.37201/req/019.2025","DOIUrl":"10.37201/req/019.2025","url":null,"abstract":"","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":"38 3","pages":"253-254"},"PeriodicalIF":0.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12095937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143589089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-14Epub Date: 2025-03-13DOI: 10.37201/req/125.2024
Ángel Rodríguez-Villodres, María Valentina Hoffmann-Álvarez, Pedro Camacho-Martínez, José Antonio Lepe
Human infections by Bordetella bronchiseptica are increasing in recent years. However, due to the lack of clinical susceptibility/resistance breakpoints, antimicrobial treatment is complex. Business Intelligence (BI) is a tool that allows to record and analyze large amounts of data in a very short time. The aim of this study was to analyze a cohort of patients with B. bronchiseptica infections focusing on how BI can help guide empirical antimicrobial therapy Demographic, clinical, and microbiological data about B. bronchiseptica infections were recovered. Then, MIC50/90 of several antibiotics was automatically calculated through the BI. Thirteen B. bronchiseptica infections were identified. The lowest MICs90 were for carbapenem, aminoglycoside, fluoroquinolones, and tetracyclines. The EUCAST PK-PD (non-species related) breakpoints showed that only piperacillin/tazobactam, imipenem and meropenem would be appropriate treatments to use empirically. In conclusion, BI systems have great potential to optimize the empirical antibiotic treatment in these types of infections.
{"title":"Usefulness of business intelligence to guide antimicrobial treatment decision in infections by infrequent microorganism such as <i>Bordetella bronchiseptica</i>.","authors":"Ángel Rodríguez-Villodres, María Valentina Hoffmann-Álvarez, Pedro Camacho-Martínez, José Antonio Lepe","doi":"10.37201/req/125.2024","DOIUrl":"10.37201/req/125.2024","url":null,"abstract":"<p><p>Human infections by <i>Bordetella bronchiseptica</i> are increasing in recent years. However, due to the lack of clinical susceptibility/resistance breakpoints, antimicrobial treatment is complex. Business Intelligence (BI) is a tool that allows to record and analyze large amounts of data in a very short time. The aim of this study was to analyze a cohort of patients with <i>B. bronchiseptica</i> infections focusing on how BI can help guide empirical antimicrobial therapy Demographic, clinical, and microbiological data about <i>B. bronchiseptica</i> infections were recovered. Then, MIC<sub>50/90</sub> of several antibiotics was automatically calculated through the BI. Thirteen <i>B. bronchiseptica</i> infections were identified. The lowest MICs<sub>90</sub> were for carbapenem, aminoglycoside, fluoroquinolones, and tetracyclines. The EUCAST PK-PD (non-species related) breakpoints showed that only piperacillin/tazobactam, imipenem and meropenem would be appropriate treatments to use empirically. In conclusion, BI systems have great potential to optimize the empirical antibiotic treatment in these types of infections.</p>","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":"38 3","pages":"208-213"},"PeriodicalIF":0.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12095938/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143627348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-14Epub Date: 2025-02-20DOI: 10.37201/req/114.2024
Patricio Favier, Carla Raffo, Diego Torres, Marcelo Gismondi, Florencia Piñeiro, Gabriela Blugerman, Marian Erbin, Johana Pérez, Omar Sued, María José Rolón
Introduction: Community-acquired methicillin-resistant Staphylococcus aureus (MRSA) is a human skin and mucosa colonizer being this colonization a risk factor for infections by this germ. It's unknown the role that domestic canines and felines (CF) play in human colonization. The objective of this study was to demonstrate the association between MRSA isolation in clinical samples from skin and soft tissue infections (SSTIs) in adults living with CF.
Material and methods: A retrospective model of cases (SSTIs with isolation of MRSA) and controls (SSTIs without isolation of MRSA) was used. We included 166 SSTI episodes treated in two hospitals, in Buenos Aires, Argentina, between October 2014 and January 2018. Samples were taken by puncture through healthy skin and the material obtained was sown in usual culture media. For bacterial identification, mass spectrometry and automated nephelometry were used. Methicillin-resistance was confirmed by disc-diffusion with cefoxitin discs. Data on living habits with CF and classic risk factors for SSTIs by MRSA were collected.
Results: Patients with SSTIs due to MRSA live more with CF (crude OR 1.9; [1.1-3.7] p<0.05) and tend to live more closely with them (crude OR 1.8; [0.99-3.43] p=0.08). In the multivariate analysis, those who live closely with CF have 1.3 times more chances of SSTIs due to MRSA (adjusted OR 2.32; [1.12-4.78] p<0.02).
Conclusions: We conclude that there is an association between human MRSA SSTIs and living with CF.
{"title":"Living with dogs and cats: Is it a risk factor for community acquired methicillin-resistant <i>Staphylococcus aureus</i> skin and soft tissue infections in humans?","authors":"Patricio Favier, Carla Raffo, Diego Torres, Marcelo Gismondi, Florencia Piñeiro, Gabriela Blugerman, Marian Erbin, Johana Pérez, Omar Sued, María José Rolón","doi":"10.37201/req/114.2024","DOIUrl":"10.37201/req/114.2024","url":null,"abstract":"<p><strong>Introduction: </strong>Community-acquired methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) is a human skin and mucosa colonizer being this colonization a risk factor for infections by this germ. It's unknown the role that domestic canines and felines (CF) play in human colonization. The objective of this study was to demonstrate the association between MRSA isolation in clinical samples from skin and soft tissue infections (SSTIs) in adults living with CF.</p><p><strong>Material and methods: </strong>A retrospective model of cases (SSTIs with isolation of MRSA) and controls (SSTIs without isolation of MRSA) was used. We included 166 SSTI episodes treated in two hospitals, in Buenos Aires, Argentina, between October 2014 and January 2018. Samples were taken by puncture through healthy skin and the material obtained was sown in usual culture media. For bacterial identification, mass spectrometry and automated nephelometry were used. Methicillin-resistance was confirmed by disc-diffusion with cefoxitin discs. Data on living habits with CF and classic risk factors for SSTIs by MRSA were collected.</p><p><strong>Results: </strong>Patients with SSTIs due to MRSA live more with CF (crude OR 1.9; [1.1-3.7] p<0.05) and tend to live more closely with them (crude OR 1.8; [0.99-3.43] p=0.08). In the multivariate analysis, those who live closely with CF have 1.3 times more chances of SSTIs due to MRSA (adjusted OR 2.32; [1.12-4.78] p<0.02).</p><p><strong>Conclusions: </strong>We conclude that there is an association between human MRSA SSTIs and living with CF.</p>","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":"38 3","pages":"187-196"},"PeriodicalIF":0.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12095934/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143495134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-14Epub Date: 2025-03-05DOI: 10.37201/req/002.2025
Alfonso Gotor-Rivera, Lucia de Jorge-Huerta, José Tiago Silva, Mario Fernández-Ruiz, Isabel Rodríguez-Goncer, María Asunción Pérez-Jacoiste Asín, Tamara Ruiz-Merlo, Carlos Heredia-Mena, Esther González-Monte, Natalia Polanco, Rafael San-Juan, Amado Andrés, José María Aguado, Francisco López-Medrano
Introduction: The increased risk of tuberculosis (TB) reactivation in solid organ transplant recipients supports the recommendation of screening for latent tuberculosis infection (LTBI). Adherence to available screening tests has not been studied in the kidney transplant (KT) population. We aimed to assess screening compliance within the ATALANTA-DOS population study.
Methods: ATALANTA-DOS studied an intervention bundle aimed at preventing infection in KT recipients. We compared LTBI screening rates between the pre-intervention (February 2016 - September 2017) and intervention (February 2018 - September 2019) cohorts and evaluated adherence rates between the interferon-gamma release assay (IGRA) and the tuberculin skin test (TST).
Results: A total of 307 KT recipients were included (155 in the pre-intervention cohort; 148 in the intervention cohort). A systematic assessment of screening compliance by an infectious disease specialist on day +30 post-KT improved LTBI screening adherence (82.6% [114/138] vs 1.3% [2/155]; p-value <0.001). In the intervention cohort, compliance was higher with IGRA (83.3% [52/62]) than with TST (68.1% [49/72]). Two cases of LTBI were detected in the pre-intervention cohort and five in the intervention cohort (4.4% [5/114]). All patients completed LTBI treatment after ruling out active TB. No cases of active TB were identified during follow-up.
Conclusions: Systematic evaluation of LTBI screening compliance significantly increased screening completion rates among KT recipients. IGRA-based strategies increased screening compliance, supporting their implementation over TST for LTBI screening among KT recipients. Increased adherence would allow a more targeted and effective treatment of LTBI.
{"title":"Optimizing compliance with latent tuberculosis infection screening among kidney transplant recipients.","authors":"Alfonso Gotor-Rivera, Lucia de Jorge-Huerta, José Tiago Silva, Mario Fernández-Ruiz, Isabel Rodríguez-Goncer, María Asunción Pérez-Jacoiste Asín, Tamara Ruiz-Merlo, Carlos Heredia-Mena, Esther González-Monte, Natalia Polanco, Rafael San-Juan, Amado Andrés, José María Aguado, Francisco López-Medrano","doi":"10.37201/req/002.2025","DOIUrl":"10.37201/req/002.2025","url":null,"abstract":"<p><strong>Introduction: </strong>The increased risk of tuberculosis (TB) reactivation in solid organ transplant recipients supports the recommendation of screening for latent tuberculosis infection (LTBI). Adherence to available screening tests has not been studied in the kidney transplant (KT) population. We aimed to assess screening compliance within the ATALANTA-DOS population study.</p><p><strong>Methods: </strong>ATALANTA-DOS studied an intervention bundle aimed at preventing infection in KT recipients. We compared LTBI screening rates between the pre-intervention (February 2016 - September 2017) and intervention (February 2018 - September 2019) cohorts and evaluated adherence rates between the interferon-gamma release assay (IGRA) and the tuberculin skin test (TST).</p><p><strong>Results: </strong>A total of 307 KT recipients were included (155 in the pre-intervention cohort; 148 in the intervention cohort). A systematic assessment of screening compliance by an infectious disease specialist on day +30 post-KT improved LTBI screening adherence (82.6% [114/138] vs 1.3% [2/155]; p-value <0.001). In the intervention cohort, compliance was higher with IGRA (83.3% [52/62]) than with TST (68.1% [49/72]). Two cases of LTBI were detected in the pre-intervention cohort and five in the intervention cohort (4.4% [5/114]). All patients completed LTBI treatment after ruling out active TB. No cases of active TB were identified during follow-up.</p><p><strong>Conclusions: </strong>Systematic evaluation of LTBI screening compliance significantly increased screening completion rates among KT recipients. IGRA-based strategies increased screening compliance, supporting their implementation over TST for LTBI screening among KT recipients. Increased adherence would allow a more targeted and effective treatment of LTBI.</p>","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":"38 3","pages":"222-227"},"PeriodicalIF":0.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12095941/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143560409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-14Epub Date: 2025-03-10DOI: 10.37201/req/003.2025
Rocío Asensi-Diez, Ángel Ballesteros-Fernández, Manuel Rouco, Begoña Tortajada-Goitia, Aránzazu Linares-Alarcón
Introduction: To analyse the concordance between theoretical and actual stratification of people living with HIV infection attending a pharmaceutical care outpatient clinic in a tertiary regional hospital.
Material and methods: Observational, retrospective, analytical, cross-sectional and single-centre study in people living with HIV infection. Study period: April 2024. Inclusion criteria: patients with HIV infection aged over 18 years who had been receiving active antiretroviral therapy (ART) for at least two years prior to inclusion. The 2022 version of the pharmaceutical care stratification model for people living with HIV infection was used. Reliability was evaluated from a qualitative perspective using Cohen's Kappa coefficient.
Results: Of the 199 patients attended during the study period, 100 were consecutively selected, of whom 93 were ultimately stratified. Men accounted for 77.41% of the cohort, with a mean age of 47.81 ± 12.53 years. The obtained stratification percentages were: Priority 1: 7.52%; Priority 2: 26.88%; Priority 3: 65.59%. Quantitative analysis of concordance between the models yielded a Cohen Kappa value of K=0.866.
Conclusions: There is a good concordance between the distribution percentages of the theoretical stratification and the actual one obtained in our study.
{"title":"[Analysis of the concordance between theoretical and real stratification in patients living with HIV infection treated at a tertiary care hospital].","authors":"Rocío Asensi-Diez, Ángel Ballesteros-Fernández, Manuel Rouco, Begoña Tortajada-Goitia, Aránzazu Linares-Alarcón","doi":"10.37201/req/003.2025","DOIUrl":"10.37201/req/003.2025","url":null,"abstract":"<p><strong>Introduction: </strong>To analyse the concordance between theoretical and actual stratification of people living with HIV infection attending a pharmaceutical care outpatient clinic in a tertiary regional hospital.</p><p><strong>Material and methods: </strong>Observational, retrospective, analytical, cross-sectional and single-centre study in people living with HIV infection. Study period: April 2024. Inclusion criteria: patients with HIV infection aged over 18 years who had been receiving active antiretroviral therapy (ART) for at least two years prior to inclusion. The 2022 version of the pharmaceutical care stratification model for people living with HIV infection was used. Reliability was evaluated from a qualitative perspective using Cohen's Kappa coefficient.</p><p><strong>Results: </strong>Of the 199 patients attended during the study period, 100 were consecutively selected, of whom 93 were ultimately stratified. Men accounted for 77.41% of the cohort, with a mean age of 47.81 ± 12.53 years. The obtained stratification percentages were: Priority 1: 7.52%; Priority 2: 26.88%; Priority 3: 65.59%. Quantitative analysis of concordance between the models yielded a Cohen Kappa value of K=0.866.</p><p><strong>Conclusions: </strong>There is a good concordance between the distribution percentages of the theoretical stratification and the actual one obtained in our study.</p>","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":"38 3","pages":"228-233"},"PeriodicalIF":0.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12095939/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143589072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}